Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
INVO Fertility, Inc. (IVF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: IVF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
Analysis of Past Performance
Type Stock | Historic Profit -76.66% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.90 - 17.04 | Updated Date 05/27/2025 |
52 Weeks Range 0.90 - 17.04 | Updated Date 05/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
INVO Fertility, Inc.
Company Overview
History and Background
INVO Fertility, Inc. focuses on commercializing and marketing the INVOcell, an alternative to more expensive infertility treatments. Founded with the goal of making fertility treatments more accessible. Milestones include FDA clearance and expansion of clinic networks.
Core Business Areas
- INVOcell Technology: Commercialization and licensing of the INVOcell system for Intravaginal Culture (IVC), an alternative to traditional IVF.
- Clinic Network: Establishing and operating INVO Centers, fertility clinics that offer the INVOcell procedure.
- Partnerships: Collaborating with existing fertility clinics to integrate the INVOcell technology into their service offerings.
Leadership and Structure
The leadership team consists of the CEO, CFO, and other key executives responsible for strategic direction and operational management. The organizational structure includes departments for sales, marketing, clinical operations, and research and development.
Top Products and Market Share
Key Offerings
- INVOcell System: The INVOcell device is a medical device used for intravaginal culture (IVC), a simplified and more accessible approach to fertility treatment compared to traditional IVF. Market share data is not readily available. Competitors include traditional IVF clinics and companies specializing in assisted reproductive technologies (ART).
Market Dynamics
Industry Overview
The fertility industry is experiencing growth due to factors such as delayed childbearing, increasing infertility rates, and advancements in assisted reproductive technologies. However, high costs of traditional IVF remain a barrier for many.
Positioning
INVO Fertility positions itself as a provider of more accessible and affordable fertility treatment options compared to traditional IVF. Their competitive advantage lies in the lower cost and simplified procedure of the INVOcell system.
Total Addressable Market (TAM)
The global fertility market is estimated to be in the billions of dollars. INVO Fertility aims to capture a portion of this market by offering a more affordable alternative to traditional IVF, thus expanding access to fertility treatment.
Upturn SWOT Analysis
Strengths
- Lower cost alternative to traditional IVF
- Simplified procedure
- Potential for wider accessibility
- Proprietary INVOcell technology
Weaknesses
- Limited clinical data compared to traditional IVF
- Smaller market presence compared to established IVF clinics
- Dependence on INVOcell technology
- Requires specialized training for clinic staff
Opportunities
- Expansion into underserved markets
- Partnerships with existing fertility clinics
- Development of new applications for INVOcell technology
- Increased awareness of INVOcell benefits
Threats
- Competition from established IVF clinics
- Negative publicity or clinical trial results
- Changes in regulations or reimbursement policies
- Technological advancements in traditional IVF
Competitors and Market Share
Key Competitors
- TNDM
- CRSP
- BMY
- IVF FLORIDA REPRODUCTIVE ASSOCIATES
Competitive Landscape
INVO Fertility has the advantage of a lower-cost treatment option. The disadvantage is the low clinic presence compared to others.
Growth Trajectory and Initiatives
Historical Growth: Growth has been dependent on adoption of INVOcell and expansion of clinics.
Future Projections: Future growth projections are based on analyst estimates. Check available sources for the most recent estimates.
Recent Initiatives: Recent initiatives include expanding INVO Center network and partnerships.
Summary
INVO Fertility, Inc. offers a low-cost alternative to traditional IVF with its INVOcell technology. The company's growth depends on clinic expansion, partnerships, and regulatory approvals. Key challenges include competition from established IVF clinics and the need for more clinical data. Their recent initiatives appear to show they are moving forward and becoming a greater competitor in the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Financial news outlets
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance are subject to change. Consult a financial professional for personalized investment recommendations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About INVO Fertility, Inc.
Exchange NASDAQ | Headquaters Sarasota, FL, United States | ||
IPO Launch date 2012-05-21 | CEO & Director Mr. Steven M. Shum | ||
Sector Healthcare | Industry Medical Devices | Full time employees 33 | Website https://www.invobioscience.com |
Full time employees 33 | Website https://www.invobioscience.com | ||
INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. It operates through Fertility Clinic Services; INVOcell Device; and Therapeutics segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. It also operates fertility clinics, including INVO Centers. In addition, the company develops NY-303, a GPC3 x NKp46 bifunctional antibody that is in Phase i/ii a monotherapy trial for the treatment of hepatocellular carcinoma; and NY-500, an AI-optimized bifunctional antibody. The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025. INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.